BACKGROUND: Intravaginal rings (IVR) for HIV prevention will likely be used by women on depot medroxyprogesterone acetate (DMPA) hormonal contraception. We used pigtailed macaques to evaluate the effects of DMPA on tenofovir disoproxil fumarate (TDF) IVR pharmacokinetics and viral shedding. METHODS: Mucosal tenofovir (TFV) levels were compared in SHIVSF162p3 -negative DMPA-treated (n=4) and normally cycling (n=6) macaques receiving TDF IVRs. Plasma viremia and vaginal shedding were determined in groups of SHIVSF162p3 -positive DMPA-treated (n=6) and normally cycling (n=5) macaques. RESULTS: Similar median vaginal fluid TFV concentrations were observed in the DMPA-treated and cycling macaques over 4 weeks (1.2×105 and 1.1.×105 ng/mL, respectively). Median plasma viremia and vaginal shedding AUC of the DMPA-treated (2.73×107 and 8.15×104 copies/mL, respectively) and cycling macaques (3.98×107 and 1.47×103 copies/mL, respectively) were statistically similar. CONCLUSIONS: DMPA does not affect TDF IVR pharmacokinetics or SHIV shedding.
BACKGROUND: Intravaginal rings (IVR) for HIV prevention will likely be used by women on depot medroxyprogesterone acetate (DMPA) hormonal contraception. We used pigtailed macaques to evaluate the effects of DMPA on tenofovir disoproxil fumarate (TDF) IVR pharmacokinetics and viral shedding. METHODS: Mucosal tenofovir (TFV) levels were compared in SHIVSF162p3 -negative DMPA-treated (n=4) and normally cycling (n=6) macaques receiving TDF IVRs. Plasma viremia and vaginal shedding were determined in groups of SHIVSF162p3 -positive DMPA-treated (n=6) and normally cycling (n=5) macaques. RESULTS: Similar median vaginal fluid TFV concentrations were observed in the DMPA-treated and cycling macaques over 4 weeks (1.2×105 and 1.1.×105 ng/mL, respectively). Median plasma viremia and vaginal shedding AUC of the DMPA-treated (2.73×107 and 8.15×104 copies/mL, respectively) and cycling macaques (3.98×107 and 1.47×103 copies/mL, respectively) were statistically similar. CONCLUSIONS:DMPA does not affect TDF IVR pharmacokinetics or SHIV shedding.
Authors: Iñaki Lete; Jose Luis Doval; Ezequiel Pérez-Campos; Rafael Sánchez-Borrego; Marta Correa; Esther de la Viuda; Mari Angeles Gómez; José Vicente González; Roberto Lertxundi; María Teresa Martínez; Nicolás Mendoza; Javier Robledo Journal: Contraception Date: 2007-06-27 Impact factor: 3.375
Authors: Summer Day; Susan M Graham; Linnet N Masese; Barbra A Richardson; James N Kiarie; Walter Jaoko; Kishorchandra Mandaliya; Vrasha Chohan; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2014-08-01 Impact factor: 3.731
Authors: Todd J Johnson; Priya Srinivasan; Theodore H Albright; Karen Watson-Buckheit; Lorna Rabe; Amy Martin; Chou-Pong Pau; R Michael Hendry; Ron Otten; Janet McNicholl; Robert Buckheit; James Smith; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2011-12-12 Impact factor: 5.191
Authors: Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Mitchell D Creinin; Leslie A Meyn; Lynn Borgatta; Kurt Barnhart; Jeff Jensen; Anne E Burke; Carolyn Westhoff; Melissa Gilliam; Caryn Dutton; Susan A Ballagh Journal: Obstet Gynecol Date: 2008-02 Impact factor: 7.661
Authors: Nina Derby; Manjari Lal; Meropi Aravantinou; Larisa Kizima; Patrick Barnable; Aixa Rodriguez; Manshun Lai; Asa Wesenberg; Shweta Ugaonkar; Keith Levendosky; Olga Mizenina; Kyle Kleinbeck; Jeffrey D Lifson; M Melissa Peet; Zachary Lloyd; Michael Benson; Walid Heneine; Barry R O'Keefe; Melissa Robbiani; Elena Martinelli; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Natalia Teleshova; José A Fernández-Romero; Thomas M Zydowsky Journal: Nat Commun Date: 2018-09-24 Impact factor: 14.919